Holen Sie sich die Stockscreener-App
1.45
8.21%
0.11
Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten
Processa Pharmaceuticals stock hits 52-week low at $1.3 - Investing.com India
Processa Pharmaceuticals stock hits 52-week low at $1.3 - Investing.com
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, ESMO Congress 2024 - MSN
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September - ForexTV.com
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September - StockTitan
Processa Pharmaceuticals Provides Product Pipeline and Financial Update - wallstreet:online
Rapid Demand in Gastroparesis Treatment Market 2024 Trends, - openPR
Processa Pharmaceuticals holds a target on positive study data By Investing.com - Investing.com Canada
Processa Pharmaceuticals reports preclinical success with NGC-Iri - Investing.com
Processa Pharmaceuticals reports preclinical success with NGC-Iri By Investing.com - Investing.com Australia
Processa Pharmaceuticals reports preclinical success with NGC-Iri - Investing.com India
Processa Pharmaceuticals reports preclinical success with NGC-Iri By Investing.com - Investing.com UK
Processa Pharmaceuticals (NASDAQ:PCSA) Price Target Cut to $6.00 by Analysts at HC Wainwright - Defense World
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri - StockTitan
Processa Pharmaceuticals stock hits 52-week low at $1.37 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $1.37 - Investing.com
Processa Pharmaceuticals stock hits 52-week low at $1.37 By Investing.com - Investing.com UK
Processa Pharmaceuticals Inc expected to post a loss of 98 cents a shareEarnings Preview - XM
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Rating Reaffirmed by HC Wainwright - Defense World
Deeper Dive: Understanding Processa Pharmaceuticals Inc (PCSA) Through its Various Ratios - The Dwinnex
3 Penny Stocks to Watch Now, 8/1/24 - MSN
Take off with Processa Pharmaceuticals Inc (PCSA): Get ready for trading - SETE News
3 Penny Stocks to Watch Now, 8/1/24 - TipRanks
Processa Pharmaceuticals Inc [PCSA] Investment Guide: What You Need to Know - Knox Daily
Is today’s surge in Processa Pharmaceuticals Inc. (NASDAQ: PCSA) justified ? - BP Journal
Imunon Inc. (NASDAQ: IMNN) could surging and here’w why - BP Journal
FDA clears Processa's breast cancer drug trial - Investing.com India
Nasdaq Down 1%; JetBlue Airways Shares Spike Higher - Benzinga
PCSA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
FDA clears Processa's breast cancer drug trial - Investing.com
Crude Oil Down 1%; Procter & Gamble Shares Fall After Q4 Results - Benzinga
Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today? - InvestorPlace
Dow Jumps 200 Points; Pfizer Earnings Top Views - Benzinga
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer - StockTitan
Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) Announces Enrollment of First Patients in Phase 2a Clinical Trial for Oral Lichen Planus - BP Journal
Processa Pharmaceuticals (NASDAQ:PCSA) and Ventyx Biosciences (NASDAQ:VTYX) Critical Contrast - Defense World
Salarius Pharmaceuticals (SLRX) drops 21% and here’s why - BP Journal
Processa Pharmaceuticals names new CFO By Investing.com - Investing.com Canada
Processa Pharmaceuticals names new CFO - Investing.com India
Processa Pharmaceuticals names new CFO - Investing.com
Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer - citybiz
Processa Pharmaceuticals Welcomes New CFO Russell Skibsted - TipRanks
Processa Pharmaceuticals appoints CFO (NASDAQ:PCSA) - Seeking Alpha
Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer - StockTitan
Clearmind Medicine Inc (CMND) briefly surges and here’s why - BP Journal
Next Big Thing in Biotech: Analysts Project 600% Gain for Innovative Pharma Company - BP Journal
Processa Pharmaceuticals (NASDAQ:PCSA) Shares Down 6.2% - Defense World
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com
Saba Capital Management buys Adams Natural Resources shares worth over $630k By Investing.com - Investing.com UK
Processa Pharmaceuticals shareholders approve key proposals - Investing.com
Alumis Inc (ALMS) Takes a Bold Step Forward with Its Initial Public Offering and sinks on debut - BP Journal
Alimera Sciences Inc. ($ALIM) Acquired by ANI Pharmaceuticals: A Strategic Expansion in Ophthalmology - BP Journal
Enviva reports monthly operating figures amid Chapter 11 proceedings By Investing.com - Investing.com
Gastroparesis Treatment Market Expected to Expand at a Steady 2024-2031 | Processa Pharmaceuticals, Inc., EVOKE ... - openPR
Processa Pharmaceuticals (NASDAQ:PCSA) Given “Buy” Rating at HC Wainwright - Defense World
Processa Pharmaceuticals Inc [PCSA] Investment Guide: What You Need to Know – Knox Daily - Knox Daily
Processa reports positive Phase 1b trial results for cancer drug By Investing.com - Investing.com Australia
Processa reports positive Phase 1b trial results for cancer drug By Investing.com - Investing.com
Processa Pharmaceuticals Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Understanding PCSA's financial ratios: A beginner's guide – US Post News - US Post News
Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference - Barchart
Processa reports positive Phase 1b trial results for cancer drug By Investing.com - Investing.com UK
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer - GlobeNewswire Inc.
FDA Review of MDMA as PTSD Drug Exposes Flawed Process - Bloomberg
Suraksha Group finally takes over Jaypee Infratech via insolvency process - Business Standard
ENDRA Life Sciences (NASDAQ: NDRA) Announces $8 Million Public Offering, Fuels Future Growth - BP Journal
First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC - OncLive
Financial Health Report: Processa Pharmaceuticals Inc (PCSA)'s Ratios Tell a Tale – DWinneX - The Dwinnex
5 Best-Performing Biotech Stocks for June 2024 - NerdWallet
1.19%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):